GlobeNewsWire · 17 Aug 2026neutral
Zentalis Pharmaceuticals announced the closing of its underwritten public offering of 26,450,000 shares of common stock, including 3,450,000 shares from the full exercise of the underwriters' option to purchase additional shares. The shares were sold at $3.50 per share, generating approximately $92.6 million in gross proceeds before deductions.
Why it matters — The completed offering provides Zentalis with additional capital to fund its ongoing clinical development of azenosertib.
GlobeNewsWire · 14 Aug 2026neutral
Zentalis Pharmaceuticals announced the pricing of an underwritten public offering of 23,000,000 shares of common stock at $3.50 per share, with expected gross proceeds of approximately $80.5 million before underwriting discounts and expenses. The offering is expected to close on August 17, 2026, and includes a 30-day underwriter option for up to an additional 3,450,000 shares.
Why it matters — ZNTL watchers would care because the offering represents a capital raise that could fund the company's ongoing clinical development of its azenosertib program.
GlobeNewsWire · 13 Aug 2026negative
Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock, and, in lieu of common stock to certain investors, pre-funded warrants to purchase common stock. The company also expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares on the same terms; the offering is subject to market conditions with no assurance as to completion, size, or terms.
Why it matters — A proposed public offering could dilute existing shareholders, so ZNTL watchers would monitor the potential impact on the company's share count and capital base.
GlobeNewsWire · 6 Aug 2026positive
Zentalis Pharmaceuticals reported its second quarter 2026 financial results and business updates, including completion of enrollment in the DENALI Part 2a and 2b trials of its investigational WEE1 inhibitor azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, with Part 2c currently enrolling and a topline readout expected in the first half of 2027. The company also reported $174.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, and stated that its accelerated approval strategy remains intact following FDA discussions.
Why it matters — ZNTL watchers would care because the company reiterated its registration-intended DENALI and ASPENOVA trial progress and cash runway into late 2027, which supports execution of its key clinical milestones including a potential accelerated approval pathway for azenosertib.
GlobeNewsWire · 3 Aug 2026neutral
On August 3, 2026, the Compensation Committee of Zentalis Pharmaceuticals' Board of Directors granted non-qualified stock options for an aggregate of 84,000 shares of common stock to two newly hired employees. The options were issued under the company's 2022 Employment Inducement Incentive Award Plan as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — A ZNTL watcher would care because this discloses recent hiring and equity-based compensation incentives, which are standard inducement grants tied to bringing new employees on board.
